Abstract: The invention provides a codon-optimized parvovirus polynucleotide composition and methods of expressing this polynucleotide in a variety of mammalian cells, including non-erythroid progenitor cells, to produce immunogenic compositions.

Abstract: The disclosure relates to erythroid progenitor cells and methods for producing parvovirus B 19 in the cells. The invention includes transformed and/or immortalized CD36+ erythroid progenitor cells permissive for B19 infection and methods for producing useful quantities of B 19 in the cells described herein. Infectious virus produced by the cells of the disclosure is useful for identifying and developing therapeutically effective compositions for treatment and/or prevention of human parvovirus B 19 infections.

Abstract: Methods are provided herein for measuring the mutational frequency of a DNA molecule in cells, for example stem cells or hematopoietic cells such as CD34+ cells or granulocytes. The method includes sequencing corresponding regions of mtDNA from a set of hematopoietic cells, or a set of clonal populations of hematopoietic cells, and comparing the sequence of the corresponding regions of mtDNA from the cells, or clonal populations of cells. The method also includes the comparison of mtDNA sequences with genomic DNA sequences. Also provided are methods for screening for an agent that has a mutagenic effect on a cell. The method includes contacting, or treating, clonal populations of cells with an agent and comparing the sequence of the mtDNA obtained from the treated clonal populations of cells, with the sequence of the corresponding region of mtDNA obtained from a control clonal populations of cells.

Abstract: The present invention relates to a method of producing non-infections parvovirus capsids and to diagnostic assays and vaccines utilizing same. The invention further relates to recombinant baculoviruses encoding parvovirus structural proteins and host cells infected therewith. The invention also relates to a method of packaging and delivering genetic information utilizing the noninfectious capsids.

Abstract: The present invention relates to a method of producing non-infections parvovirus capsids and to diagnostic assays and vaccines utilizing same. The invention further relates to recombinant baculoviruses encoding parvovirus structural proteins and host cells infected therewith. The invention also relates to a method of packaging and delivering genetic information utilizing the noninfectious capsids.

Abstract: The present invention relates to a method of producing non-infections parvovirus capsids and to diagnostic assays and vaccines utilizing same. The invention further relates to recombinant baculoviruses encoding parvovirus structural proteins and host cells infected therewith. The invention also relates to a method of packaging and delivering genetic information utilizing the noninfectious capsids.

Abstract: The present invention relates to a method of producing non-infections parvovirus capsids and to diagnostic assays and vaccines utilizing same. The invention further relates to recombinant baculoviruses encoding parvovirus structural proteins and host cells infected therewith. The invention also relates to a method of packaging and delivering genetic information utilizing the noninfectious capsids.

Abstract: The present invention relates to a parvovirus protein presenting capsid. Protein presenting capsid can be made by substituting nonparvovirus proteins, such as antigenic epitopes, ligands, enzymes, or peptide sequences, for the unique region of the parvovirus minor structural protein (e.g. VP1). Small regions of VP2 can also be replaced. Normal VP2 can be added to enhance capsid formation.

Abstract: The present invention relates to a method of producing non-infectious-parvovirus capsids and to diagnostic assays and vaccines utilizing same. The invention further relates to recombinant baculoviruses encoding parvovirus structural proteins and host cells infected therewith. The invention also relates to a method of packaging and delivering genetic information utilizing the noninfectious capsids.

Abstract: The present invention relates to a method of producing non-infections parvovirus capsids and to diagnostic assays and vaccines utilizing same. The invention further relates to recombinant baculoviruses encoding parvovirus structural proteins and host cells infected therewith. The invention also relates to a method of packaging and delivering genetic information utilizing the noninfectious capsids.

Abstract: The invention provides a method of detecting the presence of a parvovirus in a sample comprising contacting the sample with a purified receptor for a parvovirus, and detecting the presence of binding of parvovirus to the receptor, the presence of binding indicating the presence of parvovirus in the sample. The present invention also provides methods of purifying and removing parvoviruses from samples. The invention further provides a composition comprising a globoside, or the parvovirus B19 binding domain of globoside, in a pharmaceutically acceptable carrier. Also provided are methods of preventing or treating parvovirus B19 infection in a human subject by preventing the binding of parvovirus B19 to P antigen and methods of gene therapy utilizing parvovirus B19 and the parvovirus B19 cellular receptor.